Crossmark

Practical Characterization Strategies for Comparison, Qualification, and Selection of Cell Viability Detection Methods for Cellular Therapeutic Product Development and Manufacturing

Crossref DOI link: https://doi.org/10.1007/s10895-023-03382-1

Published Online: 2023-09-22

Published Print: 2024-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Huang, Yongyang

Watkins, Rachel

Patel, Samir

Pierce, Mackenzie

Franco Nitta, Carolina

Qazi, Henry

Rice, William L.

Lin, Bo

Lowe, Chris

le Sage, Carlos

Chan, Leo Li-Ying
License Information

Text and Data Mining valid from 2023-09-22

Version of Record valid from 2023-09-22
More Information

Article History

Received: 3 July 2023

Accepted: 6 August 2023

First Online: 22 September 2023

Declarations

:

: The authors Y.H., S.P., M.P., C.F.N., H.Q., W.L.R., B.L., and L.L.C. declare competing financial interests, where the AO/PI fluorescent stain and the Cellaca MX high-throughput cell counter are products of Revvity Health Sciences, Inc., an indirect parent company of Nexcelom Biosciences, LLC. The authors R.W., C.L. and C.L.S. also declare competing financial interests from Horizon Discovery Ltd., who provide cell line engineering services using functional genomics screening.

: Ethical approval is not applicable to this study since no human or animal subjects are involved.

Document is current

Any future updates will be listed below